A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis

Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMINI-I
  • Sponsors Millennium
  • Most Recent Events

    • 09 Nov 2017 According to a Takeda Pharmaceuticals media release, post-hoc analysis of this trial was presented at the 2017 Advances in Inflammatory Bowel Diseases (AIBD) annual conference.
    • 01 Nov 2017 Results of post-hoc analysis assessing the symptomatic improvement with Vedolizumab, presented at the 25th United European Gastroenterology Week.
    • 01 Nov 2017 According to a Takeda media release, post-hoc analysis from this trial will be presented at the 25th United European Gastroenterology (UEG) Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top